Isofol Medical Logo

Isofol Medical

Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.

ISOFOL | ST

Overview

Corporate Details

ISIN(s):
SE0009581051
LEI:
549300MCXYAHG7VBHX75
Country:
Sweden
Address:
C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company develops its primary drug candidate, arfolitixorin, with the aim of increasing the efficacy of first-line standard chemotherapy treatments for various solid tumors. A key area of development is colorectal cancer, where the company is conducting a Phase Ib/II clinical study to optimize the drug candidate's dosing regimen and therapeutic effect.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:00
Quarterly Report
Swedish 11.9 MB
2025-11-12 08:00
Quarterly Report
English 12.0 MB
2025-11-04 09:45
Board/Management Information
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
English 454.1 KB
2025-11-04 09:45
Board/Management Information
Isofol har utsett valberedning inför årsstämman 2026
Swedish 377.2 KB
2025-09-23 10:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-26 08:00
Interim Report
Swedish 7.2 MB
2025-08-26 08:00
Interim Report
English 2.6 MB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Isofol
Swedish 60.6 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Isofol
English 61.3 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofol's rights issue fully subscribed – exercises overallotment for Japanese p…
English 128.5 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofols företrädesemission övertecknad – utnyttjar övertilldelning till japansk…
Swedish 127.3 KB
2025-06-17 08:40
Prospectus
Isofol offentliggör prospekt i samband med bolagets företrädesemission
Swedish 98.7 KB
2025-06-17 08:40
Prospectus
Isofol publishes prospectus in connection with the company’s rights issue
English 119.6 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
English 94.5 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 11 juni 2025
Swedish 74.5 KB

Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Isofol Medical

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Isofol Medical via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-11 Magnus Hurst Other Buy 35,000 24,150.00 SEK
2022-09-12 AB Windar Other Buy 500,000 305,000.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 858.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 152.79 SEK
2021-06-14 HealthCom GmbH Other Buy 233,336 1,493,350.40 SEK
2021-06-10 Gustaf Albèrt Other Other 15,153 96,979.20 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 43,487.58 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 29,971.17 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 43,487.58 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 29,971.17 SEK

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.